Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Erika Hamilton

Erika Hamilton

MD
Sarah Cannon Cancer Center, Nashville, TN

After receiving an undergraduate degree from Washington and Lee University in Virginia, Dr. Hamilton completed her medical degree and residency from the University of North Carolina in Chapel Hill. She received her fellowship training in hematology and oncology from Duke University in Durham, North Carolina, where she was recognized as a Top 5 Finalist for Duke’s Annual House staff Fellow Teaching Award. She is board certified in internal medicine and oncology. Additionally, she is a partner with Tennessee Oncology, PLLC.

CAMBRIA 1: camizestrant ER+/HER2- early breast cancer 1:05
CAMBRIA 1: camizestrant ER+/HER2- early breast cancer
Erika Hamilton • 12 Dec 2023
Vepdegestrant + palbociclib in ER+ metastatic breast cancer: Phase Ib trial results 1:56
Vepdegestrant + palbociclib in ER+ metastatic breast cancer: Phase Ib trial results
Erika Hamilton • 12 Dec 2023
The landscape of oral SERDs and their potential in ER+ breast cancer 2:03
The landscape of oral SERDs and their potential in ER+ breast cancer
Erika Hamilton • 12 Dec 2023
Safety and tolerability of the vepdegestrant in breast cancer 2:01
Safety and tolerability of the vepdegestrant in breast cancer
Erika Hamilton • 20 Oct 2023
CAMBRIA-1: camizestrant vs standard endocrine therapy in breast cancer 0:55
CAMBRIA-1: camizestrant vs standard endocrine therapy in breast cancer
Erika Hamilton • 20 Oct 2023
Non-adherence in breast cancer treatment 1:08
Non-adherence in breast cancer treatment
Erika Hamilton • 20 Oct 2023
Resistance to ADCs in breast cancer and novel combination strategies 3:01
Resistance to ADCs in breast cancer and novel combination strategies
Erika Hamilton • 9 Jun 2023
Phase II trial of patritumab deruxtecan in metastatic breast cancer 3:03
Phase II trial of patritumab deruxtecan in metastatic breast cancer
Erika Hamilton • 9 Jun 2023
Age-stratified findings from the monarchE trial of abemaciclib in breast cancer 3:06
Age-stratified findings from the monarchE trial of abemaciclib in breast cancer
Erika Hamilton • 9 Jun 2023
DESTINY-Breast07: T-DXd+/- pertuzumab in patients with metastatic HER2+ breast cancer 2:08
DESTINY-Breast07: T-DXd+/- pertuzumab in patients with metastatic HER2+ breast cancer
Erika Hamilton • 15 Dec 2022
DESTINY-Breast02: T-DXd in HER2+ metastatic breast cancer previously treated with T-DM1 1:08
DESTINY-Breast02: T-DXd in HER2+ metastatic breast cancer previously treated with T-DM1
Erika Hamilton • 15 Dec 2022
Updated results of DESTINY-Breast03: T-DXd vs T-DM1 in metastatic HER2+ breast cancer 1:20
Updated results of DESTINY-Breast03: T-DXd vs T-DM1 in metastatic HER2+ breast cancer
Erika Hamilton • 15 Dec 2022
HER2CLIMB-05: tucatinib + trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic BC 1:47
HER2CLIMB-05: tucatinib + trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic BC
Erika Hamilton • 15 Dec 2022
What does the future hold for ADCs in breast cancer? 0:46
What does the future hold for ADCs in breast cancer?
Erika Hamilton • 12 Sep 2022
Combination therapies incorporating ADCs in breast cancer 1:02
Combination therapies incorporating ADCs in breast cancer
Erika Hamilton • 12 Sep 2022
Therapeutic strategies to maximize sensitivity to endocrine therapy in breast cancer 1:00
Therapeutic strategies to maximize sensitivity to endocrine therapy in breast cancer
Erika Hamilton • 12 Sep 2022
The content of VJOncology is intended for healthcare professionals